

*HongKong Exchanges and Clearing Limited and The Stock Exchange of HongKong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



# 廣州白雲山醫藥集團股份有限公司

GUANGZHOU BAIYUNSHAN PHARMACEUTICAL HOLDINGS CO., LTD.

*(a joint stock company with limited liability established in the People's Republic of China)*

(H Share Stock Code: 00874)

## ELECTION OF VICE CHAIRPERSON OF THE BOARD

The board (the “**Board**”) of directors (the “**Director(s)**”) of Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (the “**Company**”) is pleased to announce that Mr. Chen Jiehui (“**Mr. Chen**”) has been appointed as the vice chairperson of the 9th session of the Board of the Company, with effect from 26 September 2025 untill the conclusion of the term of the 9th session of the Board.

Biographical details of Mr. Chen is set out as follows:

Mr. Chen Jiehui, aged 50, is a member of the Communist Party of China, holds a doctoral degree, a master's degree of laws. Mr. Chen started his career in July 1995 and has successively served as the deputy chief clerk, chief clerk and deputy director of the Office of Guangzhou Taxation Bureau, the deputy director of the Office of Guangzhou Tianhe District Local Taxation Bureau, director of the office of Guangzhou Taxation Bureau and Guangzhou Local Taxation Bureau & State Taxation Administration Guangzhou Municipal Office, the deputy general manager and chief legal counsel of Guangzhou Consumer Goods and Services Group Ltd. (廣州輕工工貿集團有限公司), and has served as the chairperson of Guangzhou Daxin Creative Cultural Development Limited Company (廣州市大新文化創意發展有限公司), etc. Mr. Chen has been a director of the Company since 26 September 2025. Currently, He is the deputy secretary of the party committee, vice chairperson, general manager and chairperson of the trade union of Guangzhou Pharmaceutical Holdings Limited (廣州醫藥集團有限公司) (“**GPHL**”), and the deputy secretary of the party committee and chairperson of the trade union of the Company. Mr. Chen has extensive experience in the fields of strategic management, business management, corporate governance, compliance management, and party affairs.

The Company will enter into a service contract with Mr. Chen in relation to his appointment as an executive Director for a term commencing from 26 September 2025 and expiring on the conclusion of the term of the 9th session of the Board. Pursuant to the articles of association of the Company, Mr. Chen is eligible for re-election upon the expiry of his respective term of office. Other than as disclosed above, he has not entered into, nor is he proposing to enter into, any service contract with the Company that would require prior approval by the Company's shareholders under Rule 13.68 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”). Since Mr. Chen receives his remuneration from GPHL, the controlling shareholder of the Company, in his capacity as a member of its senior management, he will not receive any remuneration from the Company for his directorship in 2025.

As at the date of this announcement and save as disclosed above, Mr. Chen confirms that he (i) does not hold any other positions in the Company or any of its subsidiaries; (ii) does not have any relationship with any other directors, senior management, actual controllers, controlling shareholders, substantial shareholders or other shareholders of the Company holding more than 5% of the shares of the Company; (iii) does not hold any shares of the Company, nor does he have, and is not deemed to have, any interest in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong); (iv) does not hold other positions with the Company or other members of the Group (as defined under the Listing Rules); and (v) does not hold directorships in the last three years in other public companies of which the securities are listed on the securities market in Hong Kong or overseas or hold any other major appointments and professional qualifications.

Save as disclosed above, there is no other information required to be disclosed pursuant to the requirements of Rules 13.51(2)(h) to 13.51(2)(v) of the Listing Rules, nor are there any other matters that need to be brought to the attention of the shareholders of the Company.

The Board of  
**Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited**

Guangzhou, the PRC, 28 September 2025

*As at the date of this announcement, the Board comprises Mr. Li Xiaojun, Mr. Chen Jiehui, Ms. Cheng Ning, Mr. Cheng Hongjin, Mr. Tang Heping and Mr. Li Hong as executive directors, and Mr. Chen Yajin, Mr. Huang Min, Mr. Wong Lung Tak Patrick and Ms. Sun Baoqing as independent non-executive directors.*